Leeuwenberg et al. Transpl. Proc. 22(4):1991-1993, Apr. 1990.* |
Lund, J et al. J. Immunol. 147:2657-2662, Oct. 1991.* |
Morrison, SL et al. Proc. Nat. Acad. Sci. (USA). 81:6851-6855, Nov. 1984.* |
Gussow, D. and Seeman, G. Methods in Enzymology. 203:99-121, 1991.* |
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody”, Mol. Immunol., 1993, 30(1), 105-108. |
Bevilacqua et al., “Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins”, Science, 1989, 243, 1160-1165. |
Buist et al., “Kinetics and Tissue Distribution of the Radiolabeled Chimeric Monoclonal Antibody Mov18 IgG and F(ab')2 Fragments in Ovarian Carcinoma Patients”, Cancer Res., 1993, 53, 5413-5418. |
Burton et al., “Human Antibody Effector Function”, Adv. Immunol., Academic Press, 1992, 51, 1-84. |
Burton et al., “The C1q receptor site on immunoglobulin G”, Nature, 1980, 288, 338-344. |
Burton, “Immunoglobulin G: Functional Sites”, Mol. Immunol., 1985, 22(3), 161-206. |
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy”, Proc. Natl. Acad. Sci. USA, 1992, 89, 4285-4289. |
Chaiken et al., “Analysis of Macromolecular Interactions Using Immobilized Ligands”, Anal. Biochem., 1992, 201, 197-210. |
Co et al., “Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen”, J. Immunol., 1992, 148(4), 1149-1154. |
Co et al., “Humanized antibodies for antiviral therapy”, Proc. Natl. Acad. Sci. USA, 1991, 88, 2869-2873. |
Cockett et al., “The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines”, Nucl. Acids Res., 1990, 19(2), 319-325. |
Daugherty et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins”, Nucl. Acids Res., 1991, 19(9), 2471-2476. |
Duncan et al., “Localization of the binding site for the human high-affinity Fc receptor on IgG”, Nature, 1988, 332, 563-564. |
Editorials, “Antibodies to endothelial cells”, Lancet, 1991, 337, 649-650. |
Gundel et al., “Endothelial Leukocyte Adhesion Molecule-1 Mediates Antigen-induced Acute Airway Inflammation and Late-phase Airway Obstruction in Monkeys”, J. Clin. Invest., 1991, 88, 1407-1411. |
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, Nature, 1986, 321, 522-525. |
Jones et al., “Materials and Methods: Rapid PCR-Cloning of Full-length Mouse Immunoglobulin Variable Regions”, BioTechnology, 1991, 9, 88-89. |
Kabat et al., in Sequences of Proteins of Immunological Interest, 5th Edition, United States Department of Health and Human Services, 1991. |
Kabat et al., in Sequences of Proteins of Immunological Interest, 4th Edition, United States Department of Health and Human Services, 1987. |
Kohler et al., “Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion”, Eur. J. Immunol., 1976, 6, 511. |
Kramer et al., “The gapped duplex DNA approach to oligonucletide-directed mutation construction” Nucl. Acids Res., 1984, 12(24), 9441-9456. |
Leatherbarrow et al., “Effector Functions of a Monoclonal Aglycosylated Mouse IgG2a: Binding and Activation of Complement Component C1 and Interaction with Human Monocyte Fc Receptor”, Mol. Immunol., 1985, 22(4), 407-415. |
Leeuwenberg et al., “Role of ELAM-1 in Adhesion of Monocytes to Activated Human Endothelial Cells”, Scant J. Immunol., 1992, 35, 335-341. |
Molthoff et al., “Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer”, Br. J. Cancer, 1992, 65, 677-683. |
Mulligan et al., “Role of Endothelial-Leukocyte Adhesion Molecula 1 (ELAM-1) in Neutrophil-mediated Lung injury in Rats”, J. Clinical Invest., 1991, 88, 1396-1406. |
Picker et al., “ELAM-1 is an adhesion molecule for skin-homing T cells”, Nature, 1991, 349, 796-799. |
Pimm et al., “Blood and tissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy”, Nuclear Medicine Commun., 1989, 10, 585-593. |
Podolsky et al., “Attenuation of Colitis in the Cotton-top Tamarin by Anti-α4 integrin Monoclonal Antibody”, J. Clin. Invest., 1993, 92, 372-380. |
Queen et al., A humanized antibody that binds to the interleukin 2 receptor, Proc. Natl. Acad. Sci. USA, 1989, 86, 10029-10033. |
Reichmann et al., “Reshaping human antibodies for therapy”, Nature, 1988, 332, 323-327. |
Routledge et al., “A humanized monovalent CD3 antibody which can activate homologous complement”, Eur. J. Immunol., 1991, 21, 2717-2725. |
Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”, Science, 1988, 239, 1534-1536. |
Westphal et al., “Anti-endothelial cell antibodies in sera of patients with autoimmune diseases: comparison between ELISA and FACS analysis”, Clin. Exp. Immunol., 1994, 96, 444-449. |
Whittle et al., “Expression in COS cells of a mouse-human chimaeric B72.3 antibody”, Prot. Eng., 1987, 1(6), 499-505. |
Woof et al., “Localisation of the Monocyte-Binding Region on Human Immunoglobulin G”, Mol. Immunol., 1986, 23(3), 319-330. |
Xu et al., “Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement”, J. Biol. Chem., 1994, 269(5), 3469-3474. |
Yan et al., “Human/Severe Combined Immunodeficient Mouse Chimeras”, J. Clin. Invest, 1993, 91, 986-996. |
Yan et al., “Leukocyte Recruitment into Human Skin Transplanted onto Severe Combined Immunodeficient Mice Induced by TNF-αis Dependent on E-Selection”, J. Immunol., 1994, 152, 3053-3063. |